Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window | Zendy

Jeffrey L. Saver | Zendy; Jeffrey Gornbein | Zendy; James C. Grotta | Zendy; David S. Liebeskind | Zendy; Helmi L. Lutsep | Zendy; Lee H. Schwamm | Zendy; Phillip Scott | Zendy; Sidney Starkman | Zendy

Open Access

Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window

Author(s) -

Jeffrey L. Saver,

Jeffrey Gornbein,

James C. Grotta,

David S. Liebeskind,

Helmi L. Lutsep,

Lee H. Schwamm,

Phillip Scott,

Sidney Starkman

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.543561

Subject(s) - medicine , tissue plasminogen activator , intensive care medicine , fibrinolytic agent , stroke (engine) , window of opportunity , harm , therapeutic window , medical emergency , surgery , pharmacology , mechanical engineering , real time computing , computer science , law , political science , engineering

Measures of a therapy's effect size are important guides to clinicians, patients, and policy-makers on treatment decisions in clinical practice. The ECASS 3 trial demonstrated a statistically significant benefit of intravenous tissue plasminogen activator for acute cerebral ischemia in the 3- to 4.5-hour window, but an effect size estimate incorporating benefit and harm across all levels of poststroke disability has not previously been derived.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research